Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology - 2IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- 3What we know about the Brown University shooting suspect who was found dead, and how police linked him to the MIT killing
- 4They died 'doing what they loved': The stories of workers in their 80s who died on the job
- 5Exemplary Fragrances: A Manual for Notorious Scents
- Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- Trouvez La Carte De Cr\u00e9dit Id\u00e9ale Pour Vos Besoins En Belgique
- The 10 Most Noteworthy Games in History
- Philippines evacuates 3,000 villagers after volcano activity raises alert level
- The Best Games Crossroads in History
- The Delight of Perusing: Book Proposals for Each Class
- Malaysia To Revive Search for Missing Flight MH370
- IDF Givati Brigade soldier arrested, charged in suspected Iran espionage
- First SpaceX booster for upgraded Starship fails during test in Texas
